HIV Infections Clinical Trial
Official title:
A Study of Psychosocial and Behavioral Determinants of Differential Rates of Participant Compliance in CPCRA Protocols
To examine, in patients enrolled in protocols CPCRA 006 and/or 007, the relationship between
patient compliance and demographic, psychosocial, and lifestyle characteristics and Health
Belief Model premises (i.e., patient's perception of susceptibility to and severity of
disease and perception of benefits and barriers to a particular treatment) in order to
design more effective intervention protocols.
Patient noncompliance can influence the statistical findings of a clinical study, possibly
resulting in an incorrect assessment of the effects of the investigational therapeutic
agent. Since the special populations targeted by the CPCRA for inclusion in HIV-related
clinical research do not typify those traditionally included in clinical trials or
compliance research, it is necessary to elucidate and examine the special needs of these
populations and to determine the extent to which these needs manifest themselves as
potential barriers to protocol compliance.
Status | Completed |
Enrollment | 557 |
Est. completion date | September 1996 |
Est. primary completion date | September 1996 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 13 Years and older |
Eligibility |
Patients must meet the following criteria: - New enrollment on CPCRA 006 or CPCRA 007. - Life expectancy of at least 6 months. - Willing and able, in clinician's opinion, to comply with treatment and clinical management. - Able to read and write English or Spanish. - Consent of parent of guardian for patients under 18 years. |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | AIDS Research Consortium of Atlanta | Atlanta | Georgia |
United States | Bronx Lebanon Hosp Ctr | Bronx | New York |
United States | AIDS Research Alliance - Chicago | Chicago | Illinois |
United States | Denver CPCRA / Denver Public Hlth | Denver | Colorado |
United States | Comprehensive AIDS Alliance of Detroit | Detroit | Michigan |
United States | Henry Ford Hosp | Detroit | Michigan |
United States | Louisiana Comm AIDS Rsch Prog / Tulane Univ Med | New Orleans | Louisiana |
United States | Harlem AIDS Treatment Group / Harlem Hosp Ctr | New York | New York |
United States | North Jersey Community Research Initiative | Newark | New Jersey |
United States | Portland Veterans Adm Med Ctr / Rsch & Education Grp | Portland | Oregon |
United States | Richmond AIDS Consortium | Richmond | Virginia |
United States | Veterans Administration Med Ctr / Regional AIDS Program | Washington | District of Columbia |
United States | Wilmington Hosp / Med Ctr of Delaware | Wilmington | Delaware |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Simon PM, Morse EV, Besch L. Barriers to compliance among women co-enrolled in a PCP prophylaxis and compliance protocol. HIV Infect Women Conf. 1995 Feb 22-24:P109
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |